Company Profile

ActiveSite Pharmaceuticals Inc
Profile last edited on: 7/30/19      CAGE: 4GH61      UEI:

Business Identifier: Treatments for diabetic macular edema and hemorrhagic stroke
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1456 Fourth Street #C
Berkeley, CA 94710
   (510) 665-5939
Location: Single
Congr. District: 13
County: Alameda

Public Profile

ActiveSite Pharmaceuticals utilizes proprietary lead discovery technology to discover new small molecule drug candidates for human diseases with unmet medical need. The company is initially focused on developing novel, innovative treatments for the major vision-threatening complication of diabetes, diabetic macular edema, and the genetic disease hereditary angioedema, by targeting the vascular protease plasma kallikrein, Kallikrein is a vascular serine protease, circulating in blood as an inactive zymogen, prekallikrein. Upon activation, plasma kallikrein cleaves its physiological substrate high molecular weight kininogen, generating the potent inflammatory vasodilator peptide bradykinin. Binding of bradykinin to its receptors on the surface of endothelial cells lining blood vessels initiates a series of signaling events leading to the opening of intercellular junctions between endothelial cells, resulting in increased vascular permeability.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $2,409,646
Project Title: Novel Anti-Thrombotic Approach for Treatment of Myocardial Infarction

Key People / Management

  Sukanto Sinha -- Co Founder and CEO

  Tamie Chilcote -- Co-Founder and COO